For over 30 years, CAMH has been a world leader in clinical brain- positron emission tomography (PET) research worldwide. Our work in PETresearch has had a major global impact in understanding brain chemistry, leading to better clinical treatment of mental illness and addiction, and drug development. We have over 40 PET radiopharmaceuticals for neuroimaging translated for human use and over 100 labeled compounds tested in preclinical models. Since 1989, we have significantly expanded our PET research capabilities to include PET imaging, magnetic resonance imaging (MRI), pre-clinical imaging, digital autoradiography, radiochemistry production facility, and neuro-science research programs.
The Brain Health Imaging Centre houses the following:
- Two PET scanners: A Discovery MI 5 and a HRRT (High Resolution Research Tomograph);
- Two cyclotrons including a dual-particle cyclotron (Scanditronix MC-17) and a new IBA cyclone18 cyclotron;
- One MRI scanner, the 3T GE Discovery MR750 with multinuclear imaging capability.
- Two fully equipped radiochemistry laboratory including one allowing GMP production of short-lived positron emitting radiotracers tracers for human use. The radiochemistry facility houses a total of 17 HEPA-filtered hot cells (Comecer) with >10 commercial automated synthesis units (GE, Synthra, Neptis) and customized home-built apparatus for non-traditional radiochemistry.
- PET Data Analysis Laboratory with modern radiochromatography and radiopharmaceutical analysis apparatus for quality control.
- Preclinical Imaging Laboratory housing a 3T PET-MR (Mediso).
Results You Can See
- PET and PET-CT studies: Alvina Ng (Alvina.Ng@camh.ca)
- PET protocols: Kimberly Desmond (Kimberly.Desmond@camh.ca)
- MRI studies: Anusha Ravichandran (Anusha.Ravichandran@camh.ca)
- Radiochemistry inquiries: Armando Garcia (Armando.Garcia@camh.ca)
- Preclinical Imaging: Junchao Tong (Junchao.Tong@camh.ca)
- Billing: Stephanie Seto (Stephanie.Seto@camh.ca)